Itsubo M, Kameda H
First Dept. of Internal Medicine, Jikei University School of Medicine.
Gan To Kagaku Ryoho. 1989 Feb;16(2):199-206.
Intra-arterial infusion chemotherapy for various malignant tumors in order to improve the antitumor effects and to diminish the side effects has been performed in general since the 1950's. Numerous reports have shown favourable therapeutic effects followed by the development of the new anticancer agents. Although in recent years application of intra-arterial administration of anticancer agents alone has been limited to such target tumors as liver cancer because of application of mechanical arterial embolization using gelatin sponge cubes, attempts have been made to enhance the antitumor effect. In order to improve targeting and stagnancy of anticancer agents in the tumor area, drug delivery systems involving arrangement of the hemodynamics of the tumor area (balloon-occluded arterial infusion therapy, administration with vasoconstrictive agents such as noradrenaline or angiotensin II and/or as administration with various drug carriers (microcapsules, lipiodol, albumin microspheres, Degradable Starch Microspheres, liposomes, etc.) have been prepared and made available for clinical use with various tumors. Furthermore, development of totally implantable equipment of intra-arterial use for not only continuous infusion but one-shot injection of anticancer agents contributes to the treatment of patients longer and more frequently with less trouble. In the future intra-arterial infusion chemotherapy will have an important role for treatment of various malignant tumors, especially as one part of multimodal treatments, although the pharmacokinetics should be more fully-studied.
自20世纪50年代以来,为了提高抗肿瘤效果并减少副作用,人们普遍对各种恶性肿瘤进行动脉内灌注化疗。随着新型抗癌药物的研发,大量报告显示出良好的治疗效果。尽管近年来,由于使用明胶海绵块进行机械性动脉栓塞,单独动脉内给予抗癌药物的应用仅限于肝癌等靶肿瘤,但人们一直在努力增强抗肿瘤效果。为了提高抗癌药物在肿瘤区域的靶向性和滞留性,已经制备了涉及肿瘤区域血流动力学安排的药物递送系统(球囊闭塞动脉灌注疗法、与去甲肾上腺素或血管紧张素II等血管收缩剂联合给药和/或与各种药物载体(微胶囊、碘油、白蛋白微球、可降解淀粉微球、脂质体等)联合给药),并可用于各种肿瘤的临床治疗。此外,完全可植入的动脉内使用设备的开发,不仅用于连续输注,还用于一次性注射抗癌药物,有助于更长期、更频繁地治疗患者,且麻烦更少。尽管药物动力学仍需更充分地研究,但未来动脉内灌注化疗在各种恶性肿瘤的治疗中将发挥重要作用,尤其是作为多模式治疗的一部分。